Horikawa Izumi, Yamada Leo, Harris Brent T, Harris Curtis C
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Neuroscience. 2025 Jun 14;580:54-61. doi: 10.1016/j.neuroscience.2025.06.031.
Non-neuronal glial cells in the brain, such as astrocytes, play essential roles in maintaining the functional integrity of neuronal cells. A growing body of evidence suggests that cellular senescence of astrocytes, characterized by loss of proliferative potential and secretion of neurotoxic cytokines, makes significant contribution to neurotoxicity in Alzheimer's disease and a wide range of other neurodegenerative diseases. This review discusses the beneficial effects of Δ133p53α, a natural p53 protein isoform that inhibits p53-mediated cellular senescence, thereby protecting astrocytes from senescence, highlights its potential as a therapeutic target, and underscores the need for continued research in this area. Both in senescent human astrocytes in culture, whether induced by replicative exhaustion, irradiation or exposure to amyloid-β, and in brain tissues with increased senescent astrocytes from patients with Alzheimer's disease, the expression levels of endogenous Δ133p53α protein were consistently and significantly reduced. The lentiviral vector-driven expression of Δ133p53α protected cultured human astrocytes from cellular senescence and neurotoxic secretory phenotype, leading to their cellular reprogramming to a neuroprotective state associated with neurotrophic growth factors. We thus propose that Δ133p53α is worth testing as a therapeutic target that can be enhanced in a wide range of neurodegenerative diseases with accumulated senescent astrocytes, including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, and chronic traumatic encephalopathy due to traumatic brain injury. We hypothesize that a Δ133p53α-mediated cellular reprogramming approach and a senolytic or senomorphic approach, both targeting non-neuronal cells, may be complementary with each other, and may cooperate with neuron-protecting or amyloid-β-targeting therapies currently in use.
大脑中的非神经元胶质细胞,如星形胶质细胞,在维持神经元细胞的功能完整性方面发挥着重要作用。越来越多的证据表明,星形胶质细胞的细胞衰老,其特征是增殖潜能丧失和神经毒性细胞因子的分泌,在阿尔茨海默病和其他多种神经退行性疾病的神经毒性中起重要作用。本综述讨论了Δ133p53α的有益作用,它是一种天然的p53蛋白异构体,可抑制p53介导的细胞衰老,从而保护星形胶质细胞免于衰老,强调了其作为治疗靶点的潜力,并强调了在该领域持续研究的必要性。无论是在培养的衰老人类星形胶质细胞中,无论是由复制性耗竭、辐射还是暴露于淀粉样β蛋白诱导,还是在阿尔茨海默病患者衰老星形胶质细胞增加的脑组织中,内源性Δ133p53α蛋白的表达水平均持续且显著降低。慢病毒载体驱动的Δ133p53α表达可保护培养的人类星形胶质细胞免于细胞衰老和神经毒性分泌表型,导致它们细胞重编程为与神经营养生长因子相关的神经保护状态。因此,我们建议将Δ133p53α作为一个治疗靶点进行测试,它可以在包括阿尔茨海默病、肌萎缩侧索硬化症、帕金森病以及创伤性脑损伤导致的慢性创伤性脑病等多种具有衰老星形胶质细胞积累的神经退行性疾病中得到增强。我们假设,一种针对非神经元细胞的Δ133p53α介导的细胞重编程方法以及一种衰老细胞溶解或衰老细胞形态改变方法可能相互补充,并且可能与目前使用的神经元保护或淀粉样β蛋白靶向疗法协同作用。